Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00254891 · ClinicalTrials.gov registry record · Phase 3
Trial of Paclitaxel/Carboplatin + PF-3512676 vs Paclitaxel/Carboplatin Alone in Patients With Advanced Non-Small Cell Lung Cancer
A Phase 3 study, sponsored by Pfizer.
- Terminated
- Registry status
- Phase 3
- Development phase
- 828
- Enrollment target
NCT00254891: Clinical Trial Phase 3 study, sponsored by Pfizer.
NCT00254891 is a Phase 3 study that was terminated before completion, run by Pfizer. The registered enrollment target is 828 participants, roughly in line with the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00254891, a Phase 3 study, was terminated before completion, sponsored by Pfizer.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 828 participants
- Enrollment target
Study Summary
To assess the efficacy and safety of PF-3512676 administered in combination with paclitaxel/carboplatin chemotherapy as first-line treatment in patients with locally advanced or metastatic Non-Small-Cell Lung Cancer (NSCLC) and to compare it to the efficacy and safety of paclitaxel
Interventions
- DRUG Paclitaxel + Carboplatin
- DRUG PF-3512676 + Paclitaxel + Carboplatin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 828 participants |
| Start Date | 2005-11 |
| Est. Completion | 2008-07 |
| Phase | Phase 3 |
Why NCT00254891 stopped before completion
NCT00254891 is an interventional study that assigns participants to a tested intervention. The registered 828 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target.
The record links to 0 conditions, and to 2 interventions - of which Paclitaxel + Carboplatin is the first listed.
NCT00254891 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00254891 about?
NCT00254891 is a clinical study titled "Trial of Paclitaxel/Carboplatin + PF-3512676 vs Paclitaxel/Carboplatin Alone in Patients With Advanced Non-Small Cell Lung Cancer". To assess the efficacy and safety of PF-3512676 administered in combination with paclitaxel/carboplatin chemotherapy as first-line treatment in patients with locally advanced or metastatic Non-Small-Cell Lung Cancer (NSCLC) and to compare it to the efficacy and safety of paclitaxel
What is the current status of trial NCT00254891?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 828 participants. The study started on 2005-11. Estimated completion is 2008-07.
What interventions are being tested in trial NCT00254891?
The interventions under investigation include: Paclitaxel + Carboplatin (DRUG), PF-3512676 + Paclitaxel + Carboplatin (DRUG).
Who is sponsoring clinical trial NCT00254891?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00254891's enrollment target sits among peer trials
828 400th of 2000 higher than 1,601 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05124808 · 828 participants · NA
Intensive Glycemic Targets in Overweight and Obese Women With Gestational Diabetes
- NCT03547973 · 827 participants · Phase 2
Study of Sacituzumab Govitecan in Participants With Urothelial Cancer That Cannot Be Removed or Has Spread
- NCT05067283 · 830 participants · Phase 1
A Study of Calderasib (MK-1084) in KRAS Mutant Advanced Solid Tumors (MK-1084-001)
- NCT06592924 · 830 participants · Phase 3
Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia